Sugi Predict

Sugi Predict / Compounds / SCHEMBL296038

SCHEMBL296038

SCHEMBL296038

COCOCC#Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccc(C)cc2)c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 14/20 0.60
▸ MAPK12 P53778 12/20 0.60
▸ MAPK13 O15264 3/20 0.60
▸ MAPK11 Q15759 3/20 0.60
▸ DDR2 Q16832 2/20 0.60
▸ HCK P08631 8/20 0.57
▸ TNF P01375 4/20 0.57
▸ SRC P12931 3/20 0.56
▸ GSK3B P49841 2/20 0.56
▸ SYK P43405 1/20 0.56
▸ GSK3A P49840 1/20 0.56
▸ CIT O14578 1/20 0.55
▸ MUSK O15146 1/20 0.55
▸ MAP3K7 O43318 1/20 0.55
▸ RIPK2 O43353 1/20 0.55
▸ STK10 O94804 1/20 0.55
▸ MAP4K4 O95819 1/20 0.55
▸ CHEK2 O96017 1/20 0.55
▸ ABL1 P00519 1/20 0.55
▸ EGFR P00533 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299038 0.85 MAPK14 (0.69) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL294316 0.84 MAPK14 (0.56) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL299973 0.83 MAPK14 (0.61) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL30335891 0.83 MAPK14 (0.61) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL20876951 0.83 MAPK14 (0.55) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL297067 0.83 MAPK14 (0.55) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL294693 0.82 MAPK14 (0.72) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL28458603 0.81 MAPK14 (0.69) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL296092 0.81 MAPK14 (0.62) MAPK14MAPK12MAPK13MAPK11DDR2
SCHEMBL294850 0.81 MAPK14 (0.58) MAPK14MAPK12MAPK13MAPK11DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159212-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2023-04-05 — — EP disclosed
US-20220282254-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD FULCRUM THERAPEUTICS INC (US) 2022-09-08 — — US disclosed
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD FULCRUM THERAPEUTICS INC (US) 2022-05-05 — — US disclosed
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2022-04-05 — — US disclosed
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2020-12-10 — — US disclosed
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2019-07-09 — — US disclosed
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed
US-20190105312-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed
EP-1147104-B1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMA (US) 2012-03-14 — — EP disclosed
EP-2116245-A2 EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders Boehringer Ingelheim International GmbH (DE) 2009-11-11 — — EP disclosed
US-6525046-B1 Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-02-25 — — US disclosed
WO-2003005999-A2 METHODS OF TREATING CYTOKINE MEDIATED DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-01-23 — — WO disclosed
US-6506748-B2 For therapy of diseases or pathological conditions involving inflammation such as chronic inflammatory diseases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-01-14 — — US disclosed
US-6492529-B1 PHARMACEUTIC COMPOSITIONS FOR TREATING DISEASES OR PATHOLOGICAL CONDITIONS INVOLVING INFLAMMATION SUCH AS CHRONIC INFLAMMATORY DISEASES. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-12-10 — — US disclosed
US-20020065285-A1 Aromatic heterocyclic compounds as antiinflammatory agents HICKEY EUGENE R (US) 2002-05-30 — — US disclosed
US-20020058678-A1 Aromatic heterocyclic compounds as antiinflammatory agents CIRILLO PIER F (US) 2002-05-16 — — US disclosed
US-6372773-B1 TREATMENT OF INFLAMMATION, ARTHRITIS WITH UREA OR THIOUREA HETEROCYCLES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-04-16 — — US disclosed
US-6333325-B1 ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-12-25 — — US disclosed
US-6329415-B1 INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-12-11 — — US disclosed
US-6319921-B1 FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES BOERHINGER INGELHEIM PHARMACEUTICALS, INC. 2001-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, RHOXF2 MAPK14 193/4885MAPK12 528/4885MAPK13 286/4885
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 196/4885MAPK12 446/4885MAPK13 304/4885
US-20220282254-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885
US-20020065285-A1 Aromatic heterocyclic compounds as antiinflammatory agents FPR1, AHR, FPR2 MAPK14 3755/4885MAPK12 3590/4885MAPK13 3792/4885
US-20190105312-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885
US-20020058678-A1 Aromatic heterocyclic compounds as antiinflammatory agents FPR1, AHR, FPR2 MAPK14 3755/4885MAPK12 3590/4885MAPK13 3792/4885
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.